The in vitro and in vivo activities of SM-1652 were compared with those of other cephalosporins. SM-1652 possessed a wide antibacterial spectrum which included activity against Pseudomonas aeruginosa. It also exhibited potent antibacterial activities against gram-positive cocci and clinical isolates of glucose nonfermentative bacteria. Most notably, its activity against glucose nonfermentative bacteria was the highest of all of the drugs tested. The bactericidal activity of SM-1652 was compared with that of cefoperazone. The difference between the minimum bactericidal concentration and the minimum inhibitory concentration of SM-1652 was actually smaller than that of cefoperazone for Escherichia coli and clinical isolates of indole-positive Proteus spp. SM-1652 was stable for most cephalosporinases but was hydrolyzed to some extent by penicillinases. The in vivo therapeutic effect of SM-1652 against infections in mice was better than those of cefazolin and cefoxitin. The in vivo antipseudomonal activity of SM-1652 was second to that of cefsulodin.
Komatsu et al. (2) first reported on the structure and antibacterial activities of SM-1652 ( Fig.  1) , a new semisynthetic cephalosporin. According to the report of these authors, SM-1652 was as active as cefazolin against gram-positive cocci and somewhat superior to cefazolin in potency and breadth of activity against gram-negative rods, and its antipseudomonal activity was comparable to that of cefsulodin. Matsui et al. (4) and Koyama et al. (M. Koyama, N. Nakatsuru, K. Yoshinaga, H. Matsui, C. Ikeda, K. Yano, and T. Noguchi, Program Abstr. Intersci. Conf. Antimicrob. Agents Chemother. 20th, New Orleans, La., abstr. no. 149, 1982) examined the pharmacokinetics of SM-1652 in animals and humans and showed that this agent gives rise to high and persistent blood levels. Our report is concerned with the comparative in vitro activities of SM-1652 and those of other new cephalosporins against various gram-positive cocci, Enterobacteriaceae, and some glucose nonfermentative bacteria. In addition, we report on the bactericidal activity of SM-1652, its susceptibility to P-lactamases, and its efficacy against diverse experimental infections in mice.
MATERIALS AND METHODS Drugs. SM-1652 (Sumitomo Chemical Co., Ltd.), cefoperazone (Toyama Chemical Co., Ltd.), cefsulodin and cefmenoxime (Takeda Industries Ltd.), cefotaxime (Hoechst Japan Ltd.), cefmetazole (Sankyo Co., Ltd.), cefoxitin (Daiichi Seiyaku Co., Ltd.), and moxalactam (Shionogi & Co., Ltd.) were gifts from manufacturers. Other antibiotics were acquired from commercial sources.
Media. Media used in this study included heart infusion agar (Nissui Pharmaceutical Co., Ltd.), brain heart infusion agar and broth (Nissui), antibiotic medium 3 (Difco Laboratories) and peptone water (10 g of polypeptone and 5 g of NaCl in 1,000 ml of purified water).
Organisms. Standard strains for assaying antibacterial activity were stored in the Laboratory of Drug Resistance in Bacteria in Gunma University, Gunma, Japan, by the Japan Society of Chemotherapy and were maintained in gelatin disks under desiccated conditions. Clinical isolates, 1,581 of which were used for the determination of minimum inhibitory concentrations (MICs), were stored in cooked-meat medium or frozen skim milk, purified from the stock media on an appropriate agar plate, and then used for preincuba- 1.56->100 0.39-100 0.39->100 3.13->100 6.25->100 0.39->100 0.39->100 0.78->100 0.39->100 0.78-100
1.56->100 cefmetazole (6) , and cefsulodin (8) were similar to those reported elsewhere.
The activities of SM-1652, cefoperazone, cefotaxime, and cefazolin or cefsulodin against various clinical isolates are shown in Table 2 . These agents exhibited similar activities against gram-positive cocci with minor exceptions.
SM-1652 exhibited a broad spectrum but moderate levels of activity for all strains of Enterobacteriaceae tested. Cefotaxime exhibited the highest antibacterial activity against Enterobacteriaceae of all of the drugs tested, followed by cefoperazone. In contrast, SM-1652 exhibited the highest activity against glucose nonfermentative bacteria, being comparable to cefsulodin and 2 to 16 times more active than other cephems.
The mean MICs and MBCs of SM-1652 were higher than those of cefoperazone, except for P. aeruginosa isolates, for which the mean MICs and MBCs of SM-1652 were second to cefsulodin (Table 3) . On the other hand, the percentage of isolates which showed a MBC/MIC ratio of less than 2 for drugs against E. coli, K. pneumoniae, indole-positive Proteus spp., and P. aeruginosa, respectively, were as follows: SM-1652, 80, 44, 82, and 80%; cefoperazone, 72, 42, 60, and 88%; and cefsulodin against P. aeruginosa, 100%.
SM-1652 was not hydrolyzed by the common chromosomal cephalosporinases, except for that of Serratia marcescens, but was hydrolyzed to some extent by the p-lactamases of Proteus vulgaris, Pseudomonas cepacia, and Bacteroides fragilis (Table 4) . These enzymes are distinguishable from other chromosomal cephalosporinases because of their ability to hydrolyze the cefuroxime group, their smaller molecular weights, and their susceptibility to clavulanic acid and CP-45899. They are classified as cefuroxime-hydrolyzing enzymes (cefuroximase) (1).
SM-1652 was hydrolyzed to some extent by penicillinase type I (TEM I), type II (OXA I), and type IV (PSE III). Almost the same pattern of hydrolysis was observed for cefoperazone, although the hydrolyzed percentages were smaller as compared with those of SM-1652. Cefoxitin was not hydrolyzed by any ,-lactamase, and cefotaxime was hydrolyzed by the cefuroximase.
The protective effects of SM-1652 and other cephalosporins against infections in mice are shown in Table 5 . The protective activity of SM-1652 against experimental infection with E. coli ML1410 was lower than those of ceftizoxime and cefotaxime, comparable to that of cefoperazone, and superior to those of cefoxitin and cefazolin. The protective activity of SM-1652 against infection with K. pneumoniae GN6445 was comparable to that of cefazolin and lower than those of ceftizoxime, cefotaxime, and cefoperazone. Against Pseudomonas aeruginosa GN3315 infection, SM-1652 was slightly less active than cefsulodin but three times as active as cefoperazone. Cefotaxime, ceftizoxime, and carbenicillin were not effective against such infection.
DISCUSSION
In this report, we have elaborated on the broad antibacterial spectrum, high antipseudomonal activity, and high bactericidal activity of SM-1652. Its activities against various experimental infections in mice were lower than those of third-generation cephems, with the exception of P. aeruginosa infection. It has a half-life in humans (1-g bolus injection) of about 4 to 5 h and gives rise to a plasma concentration of 8 ,ug/ml for at least 24 h. This high plasma concentration may be enough to inhibit bacterial growth, although SM-1652 displayed only moderate activity against Enterobacteriaceae. Our experiment with animals was not enough to determine whether the synergistic effect of the features mentioned above is seen or not. For this purpose, some other animal experiment system, in which the pharmacokinetics of SM-1652 are more similar to those seen in humans, such as pouch infection with rabbits, will have to be undertaken.
